Carchman, Loreen

From: Oey, Jan
Sent: Friday, February 09, 2001 1:52 PM
To: Carchman, Loreen; Kinser, Robin D.; Lau, Raymond W.; Nelson, Bettie L; Roethig, Hans-Juergen; Tricker, Anthony
Cc: Walk, Roger A.
Subject: FW: Tentative timelines for the Pilot Study

FYI

-----Original Message-----
From: Jill Schultz [SMTP:jill.schultz@Covance.Com]
Sent: Friday, February 09, 2001 9:46 AM
To: Jill Schultz; Jan.Oey@pmusa.com
Cc: Roger.A.Walk@pmusa.com
Subject: Re: Tentative timelines for the Pilot Study

Please see correction below in bold for item 4. Jill

>>> Jill Schultz 2/9/01 7:50:34 AM >>>
Dear Jan,

The following timeline was discussed with the CRU and may be more feasible:

(1) Analytical validation complete: End of May 2001

(2) Start Pilot Study (enrollment): July 2001 (Final protocol June 11, IRB June 25)

(3) End of clinical part of Pilot Study: End of Sept 2001/Early Oct 2001

(4) Clinical and analytical report: January 2001 (usually 12 weeks after CRFs are received by Data Management).

Please note that these are tentative dates and may be revised based on when the analytical validations are complete. Please contact me if you have any questions.

Thank you,

Jill

>>> "Oey, Jan" <Jan.Oey@pmusa.com> 2/6/01 5:05:30 PM >>>
Dear Jill,

Please check whether or not my estimate of timelines as below will work?

(1) Analytical validation complete: May 2001

(2) Start Pilot Study (enrollment: June 2001

(3) End of clinical part of Pilot Study: August 2001

(4) Clinical and analytical report: December 2001

PM3006533746

Source: https://www.industrydocuments.ucsf.edu/docs/hfgj0001

Moreover, do you think that the "Draft No.2 Research Protocol" will be ready
for reviewing before the Meeting at Madison?

Best regards,

Jan

Confidentiality Notice: This e-mail transmission
may contain confidential or legally privileged
information that is intended only for the individual
or entity named in the e-mail address. If you are not
the intended recipient, you are hereby notified that
any disclosure, copying, distribution, or reliance
upon the contents of this e-mail is strictly prohibited.

If you have received this e-mail transmission in error,
please reply to the sender, so that we can arrange
for proper delivery, and then please delete the message
from your inbox. Thank you.

PM3006533747

Source: https://www.industrydocuments.ucsf.edu/docs/hfgj0001